Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

CPRX stock hub

Catalyst Pharmaceuticals, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

CPRXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

3.8B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

CPRX

In the news

Latest news · CPRX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E16.5

P25 12.3P50 18.4P75 33.1

Trailing P/E18.5

P25 14.9P50 23.2P75 38.5

ROE25.5

P25 -105.6P50 -46.5P75 -3.1

ROIC81

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All CPRX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

262

Groups with data

Currency

USD

Showing 262 of 262 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001369568
Company name	Catalyst Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	14888U101
Employees	182
Employees Change	1%
Employees Change Percent	0.55
Enterprise value	$3.1B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2006-11-08
Isin	US14888U1016
Last refreshed	2026-05-10
Market cap	$3.8B
Market cap category	Mid-Cap
Price	$31.15
Price currency	USD
Rev Per Employee	3,236,203.3x
Sector	Healthcare
Sic	2834
Symbol	CPRX
Website	https://catalystpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	5.63%
EV Earnings	14.45x
EV Sales Forward	4.79x
EV/EBIT	12.02x
EV/EBITDA	10.48x
EV/FCF	14.85x
EV/Sales	5.26x
FCF yield	5.48%
Forward P/E	16.52x
P/B ratio	4x
P/E ratio	18.54x
P/S ratio	6.46x
PE Ratio10 Y	16.72x
PE Ratio3 Y	17.89x
PE Ratio5 Y	16.76x
PEG ratio	1.32x
PS Forward	5.89x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	43.77%
EBITDA Margin	50.2%
FCF margin	35.42%
Gross margin	83.03%
Gross Profit	$489M
Gross Profit Growth	19.2%
Gross Profit Growth Q	7.18%
Gross Profit Growth3 Y	45.12%
Gross Profit Growth5 Y	41.72%
Net Income	$214.3M
Net Income Growth	30.78%
Net Income Growth Q	-5.79%
Net Income Growth Years	2%
Net Income Growth3 Y	37.15%
Net Income Growth5 Y	23.37%
Pretax Margin	48.14%
Profit Margin	36.39%
Profit Per Employee	$1.2M
Profitable Years	7
ROA	16.48
Roa5y	16.75
ROCE	26.94
ROE	25.49
Roe5y	25.87
ROIC	81.01
Roic5y	197.5

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	48.23%
Cagr15y	24.89%
Cagr1y	32.81%
Cagr3y	21.86%
Cagr5y	45.19%
EPS Growth	28.24
EPS Growth Q	-6.45
EPS Growth Years	2
EPS Growth3 Y	30.84
EPS Growth5 Y	18.8
FCF Growth	-12.81%
FCF Growth Q	-36.63%
FCF Growth3 Y	25.31%
FCF Growth5 Y	35.89%
OCF Growth	-12.99%
OCF Growth Q	-36.66%
OCF Growth3 Y	21.6%
OCF Growth5 Y	35.89%
Revenue Growth	19.78x
Revenue Growth Q	7.61x
Revenue Growth Quarters	21x
Revenue Growth Years	7x
Revenue Growth3 Y	40.1x
Revenue Growth5 Y	37.68x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.6
Assets	$1.1B
Cash	$709.2M
Current Assets	$894M
Current Liabilities	$147.2M
Debt	$2.8M
Debt EBITDA	$0.01
Debt Equity	$0
Debt FCF	$0.01
Equity	$954.3M
Liabilities	$149.7M
Long Term Assets	$209.9M
Long Term Liabilities	$2.6M
Net Cash	$706.4M
Net Cash By Market Cap	$18.57
Net Cash Growth	37.33%
Net Debt EBITDA	$-2.39
Net Debt Equity	$-0.74
Net Debt FCF	$-3.39
Tangible Book Value	$822.6M
Tangible Book Value Per Share	$6.71
WACC	8.19

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	6.08
Inventory Turnover	3.53
Net Working Capital	$38.1M
Quick ratio	5.69
Working Capital	$746.9M
Working Capital Turnover	$0.94

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.85%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	5,019.15%
1Y total return	32.78%
200-day SMA	22.94
3Y total return	81%
50-day SMA	25.59
50-day SMA vs 200-day SMA	50over200
5Y total return	544.93%
All Time High	32.56
All Time High Change	-4.33%
All Time High Date	2026-04-27
All Time Low	0.37
All Time Low Change	8,318.92%
All Time Low Date	2012-11-13
ATR	1.07
Beta	0.72
Beta1y	0.44
Beta2y	0.69
Ch YTD	33.46
High	31.21
High52	32.56
High52 Date	2026-04-27
High52ch	-4.33%
Low	31.13
Low52	19.05
Low52 Date	2025-09-25
Low52ch	63.52%
Ma50ch	21.71%
Premarket Change Percent	-0.14
Premarket Price	$31.12
Premarket Volume	28,865
Price vs 200-day SMA	35.78%
RSI	73.31
RSI Monthly	74.1
RSI Weekly	78.55
Sharpe ratio	0.88x
Sortino ratio	1.48
Total Return	-1.85%
Tr YTD	33.46
Tr15y	2,706.31%
Tr1m	24.65%
Tr1w	8.39%
Tr3m	27.46%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Count Top	1
Analyst Ratings	Hold
Analyst Ratings Top	Hold
Earnings EPS Estimate	$0.63
Earnings EPS Estimate Growth	-7.35
Earnings Revenue Estimate	147,960,208x
Earnings Revenue Estimate Growth	4.62x
Operating Income	$257.8M
Operating Income Growth	32.11
Operating Income Growth Q	-1.59
Operating Income Growth3 Y	36.28
Operating Income Growth5 Y	44.23
Operating margin	43.77
Price target	$31.5
Price Target Change	$1.12

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	115,326,807%
Float Percent	94.43%
Shares Insiders	5.53%
Shares Institutions	88.18%
Shares Out	122,123,884
Shares Qo Q	0.26%
Shares Yo Y	1.85%
Short Float	7.36%
Short Ratio	7.17
Short Shares	6.95

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$183.8M
Average Volume	2,819,476.1x
Bv Per Share	7.79
CAPEX	$-58,000
Ch10y	5,019.1
Ch15y	2,706.3
Ch1m	24.65
Ch1w	8.39
Ch1y	32.78
Ch3m	27.46
Ch3y	81
Ch5y	544.9
Ch6m	45.63
Change	-0.06%
Change From Open	0.03
Close	31.17
Days Gap	-0.1
Depreciation Amortization	37,873,000
Dollar Volume	139,575,892
Earnings Date	2026-05-11
Earnings Time	amc
EBIT	$257.8M
EBITDA	$295.7M
EPS	$1.68
F Score	4
FCF	$208.6M
FCF EV Yield	6.73x
FCF Per Share	$1.71
Financing CF	-16,994,000
Fiscal Year End	December
Founded	2,002
Graham Number	17.15888
Graham Upside	-44.92
Income Tax	$69.2M
Investing CF	-58,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-02-25
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-02-25
Lynch Fair Value	$39.27
Lynch Upside	26.06
Ma150	23.81
Ma150ch	30.84%
Ma20	27.94
Ma20ch	11.51%
Net CF	191,618,000
Next Earnings Date	2026-05-11
Open	31.14
Optionable	Yes
P FCF Ratio	18.24
P OCF Ratio	18.23
Position In Range	25
Post Close	31.15
Postmarket Change Percent	-0.1
Postmarket Price	$31.12
Ppne	2,972,000
Pre Close	31.17
Price Date	2026-05-08
Price EBITDA	$12.87
Ptbv Ratio	4.62
Relative Volume	1.59x
Revenue	588,989,000x
SBC By Revenue	4.21x
Share Based Comp	24,778,000
Tax By Revenue	11.75x
Tax Rate	24.4%
Tr6m	45.63%
Us State	Florida
Volume	4,480,767
Z Score	13.56

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does CPRX pay a dividend?

Capital-return profile for this ticker.

Performance

CPRX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns CPRX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+88.2%

Float: +94.4% of shares outstanding

Insider ownership

+5.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

CPRX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

73.3

Above 70: short-term overbought

Price vs 200-day MA

+35.8%

50/200-day relationship not available

Beta (5Y)

0.72

Less volatile than the market

Sharpe ratio

0.88

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About CPRX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current CPRX stock rating?

Catalyst Pharmaceuticals, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full CPRX analysis?

The full report lives at /stocks/CPRX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for CPRX?

The latest report frames CPRX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the CPRX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.